|
Business Development RegeneRx intends to partner strategically with companies with clinical development and commercialization strengths in desired pharmaceutical therapeutic fields. We are actively seeking partnerships with suitable infrastructure, expertise and a long-term initiative in our focus disease areas. In 2004, RegeneRx entered into a partnership with Sigma-Tau Group’s wholly-owned subsidiary, Defiante Farmaceutica L.d.a., for development and marketing of RGN-137, and certain indications relating to RGN-352, in Europe and certain contiguous countries. Sigma-Tau is fully funding and managing a dermal phase II trial in the EU for the treatment of venous stasis ulcers. Another partnership initiative involves our peptide fragments. Our goal is to out-license these fragments for various cosmeceutical applications to companies that specialize in formulation, manufacturing, development and commercialization in this growing market segment. To inquire about partnership opportunities with RegeneRx contact: Debra Bowes |